



sawai

Sawai Group Holdings Co., Ltd.

Presentation Materials FY2026 Q1

August 10, 2026
4887, TSE Prime



■ Results for the First Three Months of FY2026 (Ended March 31,2027)

- Revenue increased 4.3% YoY, core operating profit decreased 15.4% YoY, and operating profit decreased 29.0% YoY.
 - ⊕ Increased sales of products listed in FY2025 and FY2026
 - ⊖ Sales decline in existing products due to NHI drug price revisions
 - ⊖ Incurrence of inventory valuation and disposal losses
 - ⊖ Increased in fixed costs due to higher headcount

■ Production volume (included outsourced production)

- Production volume for Q1 FY2026 was 4.4 billion tablets (Increased 13.0% YoY / Increased 500 million tablets YoY)
- Progress rate 24.5% (annual plan for FY2026 of 18.0 billion tablets)

■ Sales volume

- Sales volume for Q1 FY2026 4.3 billion tablets (Increased 2.7% YoY / Increased 100 million tablets YoY)
- Progress rate 24.8% (annual plan for FY2026 of 17.6 billion tablets)

■ Supply status

- Current number of items for which shipment is restricted or suspended: 139 items; regular shipment: 603 items (as of June 30, 2026)
- Increased number of shipment-restricted items due to supply tightness in some products
- Reviewing item-by-item production plans to promote strengthening of supply capacity with priority given to products that are difficult to substitute

Overview of Financial Results for Q1 FY2026

sawai

YoY change

- Sales growth driven by strong sales of products listed in December 2025 and in June 2026
- Gross profit margin declined due to inventory valuation and disposal losses
- Incurrence of R&D impairment losses

(Unit: million yen)

	Q1 FY2025 results	Q1 FY2026 results	YoY	Full-Year forecasts	Progress
Revenue	49,511	51,622	+4.3%	208,400	24.8%
Gross profit	15,438	15,076	(2.3)%	65,500	23.0%
Core operating profit	7,597	6,425	(15.4)%	29,600	21.7%
Operating profit	6,979	4,953	(29.0)%	27,200	18.2%
Profit before tax	6,802	4,445	(34.7)%	26,000	17.1%
Profit attributable to owners of the Company	4,891	2,429	(50.3)%	18,600	13.1%

Average rate

US\$1=¥145

US\$1=¥159


* The line items from revenue through profit before tax show the amount of the Japan business as continuing operations. Profit attributable to owners of the Company shows the combined amount of the continuing operations and the discontinued operations.

* Core operating profit is calculated by excluding profits and losses attributed to non-recurring factors from operating profit.

* (Breakdown of interim profit attributable to owners of the parent company) FY2025 Q1: Continuing operations 4,856 million yen, Discontinued operations 35 million yen
FY2026 Q1: Continuing operations 2,863 million yen, Discontinued operations (433) million yen

Revenue by Product Listed Year


- Products listed in December 2025 performed strongly, led by Dapagliflozin
- Products listed in June 2026 are also off to a strong start
- Many products listed in or before 2023 saw revenue declines, mainly due to drug price revisions



Operating Profit Analysis

sawai

(Unit: million yen)






Reference Materials

Strategies for Production Capacity Expansion

- Impact on production from the Kumamoto Earthquake was minimal.
- Scheduled launch of Step 2 at Daini Kyushu Factory new building in Dec 2026.
- Proceeding with product transfers to the new building at Daini Kyushu Factory and Trust Pharmatech
- Continue to consider making additional investments, including construction of own factories and alliance with other companies, to achieve in-house production capacity of 25.0 billion tablets in FY2030.



*Assumptions for production capacity: Continuous operations of machines in two shifts on weekdays for the current number of items. The number of items produced under contract manufacturing is not included.

Comparison of Sales Volume by Therapeutic Area

	Q1 FY2025 Composition(volume)	Q1 FY2026 Composition(volume)	YoY change (volume)	YoY change (value)
Cardiovascular drugs	27.3%	27.2%	+2.6%	+1.4%
Central nervous system drugs	15.9%	16.0%	+3.4%	+6.5%
Gastro-intestinal drugs	15.6%	14.8%	(2.9)%	(3.5)%
Other metabolic drugs	8.9%	9.7%	+12.1%	+33.5%
Blood/body fluid pharmaceutical products	8.3%	9.7%	+20.5%	(0.9)%
Vitamin drugs	5.3%	5.5%	+6.1%	(1.0)%
Antiallergic drugs	4.7%	4.7%	+3.3%	+4.5%
Respiratory organ agents	5.2%	3.7%	(27.0)%	(24.3)%
Others	8.8%	8.6%	+0.5%	+2.1%
Total	100.0%	100.0%	+2.7%	+4.3%


Consolidated Financial Highlights 1

sawai

Consolidated Statements of Financial Position

End of March 2026

Total assets 359.9




Ratio of equity attributable to owners of the Company to total assets: **49.6%**

Net D/E ratio: **0.43**

End of June 2026

(Unit: billion yen)

Total assets 369.0



Ratio of equity attributable to owners of the Company to total assets: **48.1%**

Net D/E ratio: **0.52**

Consolidated Financial Highlights 2

sawai

Consolidated Statements of Cash Flows

(Unit: million yen)

	Q1 FY2025 results	Q1 FY2026 results	YoY change	Factors
Operating CF	(13,405)	(427)	+12,978	• Profit before tax: +4,445 • Depreciation and amortization: +4,347 • Increase in inventory: (7,970)
Investing CF	(8,598)	(12,706)	(4,108)	• Acquisition of property, plant and equipment: (10,584) • Acquisition of intangible assets: (2,023)
Financing CF	10,545	10,197	(348)	• Net increase acquisition of short-term borrowings: +15,647 • Repayments of long-term borrowings: (1,711) • Dividends paid: (3,234)
Cash and cash equivalents at end of the period	27,280	26,059	(1,221)	

Consolidated Financial Highlights 3

sawai

■ Key Income Statement Data

(Unit: million yen)

	FY2025 Results		FY2026 Results			FY2026 Forecasts								
	Q1	% of revenue	Q1	% of revenue	YoY	H1	% of revenue	YoY	H2	% of revenue	YoY	Full-year	% of revenue	YoY
Revenue	49,511	100.0%	51,622	100.0%	+4.3%	101,000	100.0%	+2.2%	107,400	100.0%	+4.4%	208,400	100.0%	+3.3%
Cost of sales	34,074	68.8%	36,546	70.8%	+7.3%	68,900	68.2%	(0.3)%	74,000	68.9%	+0.3%	142,900	68.6%	+0.0%
Gross profit	15,438	31.2%	15,076	29.2%	(2.3)%	32,100	31.8%	+7.9%	33,400	31.1%	+15.0%	65,500	31.4%	+11.4%
SG&A expenses	6,032	12.2%	7,020	13.6%	+16.4%	13,600	13.5%	+13.6%	14,400	13.4%	+2.3%	28,000	13.4%	+7.5%
R&D expenses	2,420	4.9%	2,974	5.8%	+22.9%	5,400	5.4%	+3.0%	4,900	4.6%	(31.4)%	10,300	4.9%	(16.9)%
Other income (expenses)	(6)	-	(128)	-	-	-	-	-	-	-	-	-	-	-
Core operating profit	7,597	15.3%	6,425	12.4%	(15.4)%	14,300	14.2%	+3.9%	15,300	14.3%	+38.9%	29,600	14.2%	+19.5%
Operating profit	6,979	14.1%	4,953	9.6%	(29.0)%	13,100	13.0%	+53.5%	14,100	13.1%	+91.6%	27,200	13.1%	+71.1%
Profit before tax	6,802	13.7%	4,445	8.6%	(34.7)%	12,500	12.4%	+57.0%	13,500	12.6%	+113.9%	26,000	12.5%	+82.2%
Profit attributable to owners of the Company	4,891	9.9%	2,429	4.7%	(50.3)%	8,900	8.8%	+52.2%	9,700	9.0%	+111.2%	18,600	8.9%	+78.2%

Consolidated Financial Highlights 4

sawai

■ Adjustment from Full Basis to Core Basis

(Unit: million yen)

	Q1 FY2025 results			Q1 FY2026 results		
	Full basis	Adjustment	Core basis	Full basis	Adjustment	Core basis
Revenue	49,511	–	49,511	51,622	–	51,622
Cost of sales	(34,074)	26	(34,047)	(36,546)	98	(36,448)
Gross profit	15,438	26	15,464	15,076	98	15,174
SG&A expenses	(6,032)	142	(5,890)	(7,020)	192	(6,828)
Amortization of intangible assets	(133)	133	–	(175)	175	–
Other	(10)	10	–	(17)	17	–
R&D expenses	(2,420)	443	(1,977)	(2,974)	1,053	(1,921)
Amortization	(440)	440	–	(528)	528	–
Impairment loss	–	–	–	(525)	525	–
Other	(3)	3	–	–	–	–
Other income	20	(20)	–	102	(102)	–
Other expenses	(26)	26	–	(230)	230	–
Operating profit	6,979	618	7,597	4,953	1,472	6,425

Consolidated Financial Data

sawai

Sales and Production Volume

(Unit: billion tablets)

	Q1 FY2025	Q1 FY2026		FY2026 full-year	
	Results	Results	YoY change	Forecasts	YoY change
Sales volume	4.2	4.3	+2.7%	17.6	+2.9%
Production volume	3.9	4.4	+13.0%	18.0	+8.4%

Capital Investment, and Depreciation and Amortization

(Unit: million yen)

	Q1 FY2025 results	Q1 FY2026 results	FY2026 full- year forecasts
Capital investment	1,780	9,534	22,100
Depreciation and amortization	3,859	4,347	17,500
Manufacturing Division	2,708	2,991	12,100
R&D Division	692	800	3,100
Administration Div. & Business Div.	459	556	2,400

Personnel Information (Number of Employees)

	FY2025		FY2026	
	End of June	Composition	End of June	Composition
Manufacturing Division	2,579	72.7%	2,850	73.9%
R&D Division	312	8.8%	323	8.4%
Administration Div. & Business Div.	655	18.5%	685	17.8%
MRs *	372	-	368	-
Total	3,546	100.0%	3,858	100.0%

* The number of MRs includes contract employees.

Disclaimer

Forward-looking statements contained in this document are based on several assumptions and do not guarantee or assure the achievement of projected figures and the implementation of initiatives.

Contact

Sawai Group Holdings Co., Ltd.

IR Group, Group Finance Department

E-Mail

ir@sawai.co.jp